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ARTICLE
Recurrent hotspot mutations in HRAS Q61 and
PI3K-AKT pathway genes as drivers of breast
adenomyoepitheliomas
Felipe C. Geyer1,2,3, Anqi Li1,4, Anastasios D. Papanastasiou1,5, Alison Smith6, Pier Selenica1, Kathleen A. Burke1,
Marcia Edelweiss1, Huei-Chi Wen1, Salvatore Piscuoglio 1,7, Anne M. Schultheis1, Luciano G. Martelotto1,
Fresia Pareja1, Rahul Kumar1, Alissa Brandes1, Dan Fan1,8, Thais Basili1, Arnaud Da Cruz Paula1,
John R. Lozada 1, Pedro Blecua9, Simone Muenst7, Achim A. Jungbluth1, Maria P. Foschini10, Hannah Y. Wen1,
Edi Brogi1, Juan Palazzo11, Brian P. Rubin12, Charlotte K.Y. Ng 1,7,13, Larry Norton14, Zsuzsanna Varga15,
Ian O. Ellis16, Emad A. Rakha16, Sarat Chandarlapaty 6, Britta Weigelt1 & Jorge S. Reis-Filho1,6
Adenomyoepithelioma of the breast is a rare tumor characterized by epithelial−myoepithelial
differentiation, whose genetic underpinning is largely unknown. Here we show through
whole-exome and targeted massively parallel sequencing analysis that whilst estrogen
receptor (ER)-positive adenomyoepitheliomas display PIK3CA or AKT1 activating mutations,
ER-negative adenomyoepitheliomas harbor highly recurrent codon Q61 HRAS hotspot
mutations, which co-occur with PIK3CA or PIK3R1 mutations. In two- and three-dimensional
cell culture models, forced expression of HRASQ61R in non-malignant ER-negative breast
epithelial cells with or without a PIK3CAH1047R somatic knock-in results in transformation and
the acquisition of the cardinal features of adenomyoepitheliomas, including the expression of
myoepithelial markers, a reduction in E-cadherin expression, and an increase in AKT signal-
ing. Our results demonstrate that adenomyoepitheliomas are genetically heterogeneous, and
qualify mutations in HRAS, a gene whose mutations are vanishingly rare in common-type
breast cancers, as likely drivers of ER-negative adenomyoepitheliomas.
DOI: 10.1038/s41467-018-04128-5 OPEN
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Adenomyoepithelioma of the breast is a rare biphasictumor composed of epithelial and myoepithelial cells1,which typically displays a benign clinical course, but may
recur locally2 and/or metastasize3. Phenotypically, adenomyoe-
pitheliomas are heterogeneous. The epithelial component may
express estrogen receptor (ER) and progesterone receptor (PR);
however, a subset of adenomyoepitheliomas lacks the expression
of hormone receptors altogether1. Both the epithelial and
myoepithelial compartments can expand and undergo malignant
transformation, histologically characterized by nuclear atypia,
mitotic activity, and/or necrosis1,2,4. Importantly, however,
metastases have been documented even in cases lacking a histo-
logically overt malignant component3. Interestingly, most inva-
sive breast cancers arising in adenomyoepitheliomas display a
triple-negative phenotype (ER-, PR- and HER2-negative) and
metaplastic features1.
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The genomic landscape of breast cancers has been extensively
investigated (reviewed in Ng et al.5). Large-scale massively par-
allel sequencing studies have revealed that breast cancers display a
complex repertoire of somatic mutations, that TP53 (37%),
PIK3CA (36%), and GATA3 (11%) are the only three genes
recurrently mutated in >10% of unselected breast cancers, and
that the repertoire of somatic mutations differs between ER-
positive and ER-negative disease; however, no pathognomonic
mutations underpinning ER-positive or ER-negative breast can-
cers have been identiﬁed6,7. These analyses, however, primarily
focused on the common forms of breast cancer6–8, whereas the
genetic characteristics of rare forms of breast tumors, including
those with myoepithelial differentiation, remain largely unex-
plored5. In fact, genomic analyses of adenomyoepitheliomas,
based on case reports or small series of cases, have demonstrated
the presence of a t(8;16)(p23;q21) chromosomal translocation in
a single case9 or a TP53 R270C missense mutation in another10.
The landscape of somatic genetic alterations of adenomyoe-
pitheliomas, however, has yet to be characterized.
Here we report on a combination of whole-exome (WES) and
targeted capture massively parallel sequencing analyses that
revealed that adenomyoepitheliomas are genetically hetero-
geneous and that, akin to common-type breast cancers, their
repertoire of somatic mutations vary according to their ER status.
In ER-negative adenomyoepitheliomas, recurrent HRAS Q61
hotspot mutations co-occur with mutations affecting PI3K
pathway genes. In non-malignant triple-negative breast epithelial
cells with or without a somatic knock-in of a PIK3CA H1047R
mutation, forced expression of mutant HRAS promotes growth
advantage, the acquisition of features consistent with myoe-
pithelial differentiation, and activation of PI3K-AKT and MAPK
signaling pathways, likely acting as a driver of ER-negative
adenomyoepitheliomas.
Results
Clinical and histologic features of adenomyoepitheliomas.
Adenomyoepitheliomas were retrieved from the authors’ insti-
tutions after approval by the local Institutional Review Boards
(IRBs). Upon central histologic review, 43 cases were considered
bona ﬁde adenomyoepitheliomas, of which 18 (42%) displayed
atypical histologic features suggestive of a more aggressive
behavior (i.e. marked nuclear pleomorphism, high mitotic rate,
and/or necrosis1; Fig. 1, Supplementary Data 1). Immunohisto-
chemical analysis revealed that 16 adenomyoepitheliomas (37%)
lacked ER expression (Fig. 1g, Supplementary Figs. 1a−l), a fea-
ture that was signiﬁcantly associated with nuclear pleomorphism,
increased mitotic rate, and higher Ki-67 labeling indices (P < 0.05,
Fisher’s exact tests, Fig. 1h−i, Supplementary Data 1, Supple-
mentary Fig. 1). AR was expressed in ≥10% of tumor cells (the
cut-off employed to select patients for potential anti-androgen
therapy11) in all but one (26/27, 96%) ER-positive adenomyoe-
pitheliomas, but in 9/16 (56%) ER-negative adenomyoepithelio-
mas (P < 0.01, Fisher’s exact test, Fig. 1i, Supplementary Figs. 1c,
i). All adenomyoepitheliomas studied lacked HER2 protein
overexpression and displayed focal p53 expression suggestive of
an unaltered TP53 status (Fig. 1i, Supplementary Data 1, Sup-
plementary Figs. 1f, l). As expected, the vast majority of adeno-
myeopitheliomas (88%) displayed strong p63 expression in the
myoepithelial component (Supplementary Figs. 1d, j).
Seven adenomyoepitheliomas (16%) were associated with
invasive carcinoma: six present in the primary tumor and one
in the ipsilateral breast recurrence (Fig. 1e, Supplementary Data 1,
Supplementary Figs. 1m−x). The ER status of paired adeno-
myoepitheliomas and carcinomas was concordant in all but one
case; in the ER-positive AM46, the invasive carcinoma of spindle
cell metaplastic type lacked ER expression. Three ER-negative
adenomyoepitheliomas developed local recurrences and/or had
axillary lymph-node metastases (Supplementary Fig. 1, Supple-
mentary Data 1). Consistent with previous reports of biphasic
metastases of adenomyoepitheliomas3, the metastases observed in
these cases retained the epithelial−myoepithelial phenotype
(Fig. 1, Supplementary Fig. 1f), suggesting that at least in some
cases, the epithelial and myoepithelial cell populations likely share
a common cell of origin with dual-lineage potential.
Adenomyoepitheliomas harbor recurrent HRAS Q61 muta-
tions. To deﬁne the genomic landscape of adenomyoepithelio-
mas, DNA samples extracted from 31 tumor-normal pairs of
adenomyoepitheliomas (Supplementary Data 1) were subjected to
WES (n= 10, median depth of coverage of tumor 159× (range
117×–167×) and normal 95× (range 69×–175×) samples) or
targeted capture massively parallel sequencing due to limited
yields of DNA available (n= 21, median depth of coverage of
tumor 434× (range 252×–749×) and normal 401× (range
83×–897×) samples), using the Memorial Sloan Kettering-
Integrated Mutation Proﬁling of Actionable Cancer Targets
(MSK-IMPACT). This sequencing assay targets all coding regions
of 410 key cancer genes and intronic and regulatory regions of
selected genes (Supplementary Data 2). In addition, the TERT
gene promoter region was investigated in all cases by MSK-
IMPACT and/or Sanger sequencing.
Adenomyoepitheliomas displayed a low mutation burden, with
a median of 17 (range 5−63) somatic mutations as deﬁned by
WES, of which 13.5 (range 4–47) were non-synonymous, whereas
Fig. 1 Histologic and immunohistochemical features of adenomyoepitheliomas. a−f Representative micrographs of hematoxylin-and-eosin (H&E)-stained
adenomyoepitheliomas included in this study. a Low-power magniﬁcation of AM2, a multilobulated lesion, of tubular architectural pattern, with well-
circumscribed borders (scale bar, 1 mm). b Intermediate-power magniﬁcation of AM39 displaying the typical bi-layered glandular architecture of
adenomyoepitheliomas, comprising abluminal myoepithelial cells with clear cytoplasm and inner cuboidal epithelial cells with eosinophilic cytoplasm and
apical snouts (scale bar, 200 μm). c AM9 displaying areas of comedo-like necrosis (*, scale bar, 200 μm). d AM8 displaying nuclear atypia and mitotic
ﬁgures (arrowheads, scale bar, 100 μm). e AM5 displaying an adenomyoepithelioma component (lower left corner, *) in association with a larger high-
grade myoepithelial carcinoma (**), with large central necrosis in the upper right corner (***, scale bar, 1 mm). f Axillary lymph node metastasis of AM5
(scale bar, 1 mm), where the biphasic architecture is maintained. *, residual lymph node; **, metastatic lesion. g Representative micrographs of estrogen
receptor (ER)-negative and ER-positive adenomyoepitheliomas. On the left, H&E stain of each case (scale bars, 100 μm). On the right, ER
immunohistochemistry results. Note the internal positive control (*) in the ER-negative case. h Stacked bar plots showing the frequency of histologic
features indicative of a more aggressive behavior (nuclear grade, mitotic rate, and necrosis) and of the presence of associated carcinoma according to ER
status (ER-positive versus ER-negative comparisons were performed using two-tailed Fisher’s exact tests). The histologic features are color-coded
according to the legends. AME, adenomyoepithelioma. i Stacked bar plots showing the frequency of the expression of androgen receptor, HER2, Ki67, and
p53 according to ER status (ER-positive versus ER-negative comparisons were performed using two-tailed Fisher’s exact tests). AME,
adenomyoepithelioma; AR, androgen receptor; Equiv, equivocal; Neg, negative; Pos, positive
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the MSK-IMPACT assay detected a median of 2 (range 0–7)
somatic mutations, of which 2 (range 0–6) were non-synonymous
(Supplementary Data 2). Compared to common forms of invasive
breast cancers from The Cancer Genome Atlas (TCGA) dataset
(median 46, range 10−396)6, adenomyoepitheliomas subjected to
WES were found to have signiﬁcantly fewer somatic mutations (P
< 0.0001, Wilcoxon test). By WES, ER-negative adenomyoepithe-
liomas displayed a numerically but not statistically signiﬁcant
higher number of somatic mutations than ER-positive adeno-
myoepitheliomas (22 (range 6–36) versus 14 (range 5–63), P >
0.1, Wilcoxon test). In agreement with the immunohistochem-
istry analysis, TP53, the gene most frequently mutated in breast
cancer and mutated in up to 80% of ER-negative breast cancers6,
was not found to be altered in any of the adenomyoepitheliomas
analyzed in this study.
Despite the low mutation burden, mutational analysis revealed
recurrently mutated genes, including PIK3CA (16/31, 52%),
HRAS (8/31, 26%), AKT1 (4/31, 13%), and PIK3R1 (4/31, 13%).
The PIK3CA mutations preferentially affected mutation hotspots
(six H1047R, ﬁve E545K, and one E542K hotspot mutations). All
HRAS mutations affected the mutation hotspot Q61, and all
AKT1 mutations were the E17K hotspot mutation (Fig. 2,
Supplementary Data 3). In four adenomyoepitheliomas (AM1,
AM27, AM43, and AM46), dual PIK3CA mutations were
identiﬁed, and in AM5 and AM52, dual PIK3R1 small deletions
were detected. Of the 38 mutations affecting these four genes
detected by WES or MSK-IMPACT, 34 (89%) were found to be
clonal by ABSOLUTE12 (Supplementary Fig. 2a, Supplementary
Data 3). Additional cancer genes recurrently mutated in
adenomyoepitheliomas included TERT (4/31, 13%, all hotspot
promoter mutations) and PRKAR1A (2/31, 6%, Fig. 2, Supple-
mentary Data 3). Likely pathogenic mutations affecting single
tumors included an ERBB3 D297Y hotspot mutation in a
PIK3CA-mutant and HRAS-wild-type adenomyoepithelioma
(Fig. 2, Supplementary Data 3).
Importantly, however, differences were observed in the
repertoire of somatic mutations of adenomyoepitheliomas:
AKT1 hotspot mutations were solely found in ER-positive lesions
(24% versus 0%, P= 0.1074, Fisher’s exact test), PIK3R1 small
deletions were only detected in ER-negative adenomyoepithelio-
mas (29% versus 0%, P= 0.0318, Fisher’s exact test), and
HRAS Q61 hotspot mutations were restricted to ER-negative
adenomyoepitheliomas (57% versus 0%, P= 0.0004, Fisher’s
exact test) and always co-occurred with PIK3CA or PIK3R1
somatic mutations (Fig. 2, Supplementary Data 3).
To validate the HRAS, PIK3CA, and AKT1mutations identiﬁed
by WES or MSK-IMPACT, Sanger sequencing of the hotspot loci
was performed in the initial 31 cases and 12 additional
adenomyoepitheliomas, for which sufﬁcient DNA could not be
obtained for massively parallel sequencing. All PIK3CA, HRAS,
and AKT1 hotspot mutations were validated in the index cases,
and four, one, and one mutations were detected in PIK3CA,
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Fig. 2 Repertoire of somatic genetic alterations in breast adenomyoepitheliomas. Heatmap depicting the somatic genetic alterations identiﬁed in 31 breast
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asterisk. In cases subjected to WES, hotspot mutations affecting the promoter of TERT were investigated by Sanger sequencing. Hotspot mutations were
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HRAS, and AKT1, respectively, in the 12 additional cases (Fig. 3a,
Supplementary Fig. 2b, Supplementary Data 3). Mutations
affecting PIK3CA, AKT1, and PIK3R1 were found to be
signiﬁcantly mutually exclusive (n= 43, P= 0.0004, CoMEt exact
test), whereas all HRAS mutations signiﬁcantly co-occurred with
PIK3CA or PIK3R1 mutations (n= 43, P value for co-occurrence
= 0.025, Z test).
In ER-positive adenomyoepitheliomas, mutations affecting
PIK3CA or AKT1 were found in 59% (16/27) of cases, whereas
in ER-negative adenomyoepitheliomas, mutations affecting
PIK3CA or PIK3R1 were detected in 81% of the cases tested
(Fig. 3a). Within ER-positive adenomyoepitheliomas, the pre-
sence of PIK3CA or AKT1 mutations was signiﬁcantly associated
with marked nuclear pleomorphism and moderate-to-high
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Fig. 3 Somatic mutations affecting HRAS and PI3K-AKT pathway-related genes in breast adenomyoepitheliomas. a Heatmap depicting somatic mutations
affecting HRAS, PIK3CA, AKT1, and PIK3R1 identiﬁed in 43 breast adenomyoepitheliomas by (i) both massively parallel sequencing (WES or MSK-IMPACT)
and Sanger sequencing or (ii) Sanger sequencing only. Cases are shown in columns (estrogen receptor (ER)-negative cases on the left; ER-positive cases
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b Spectrum of somatic mutations affecting HRAS, PIK3CA, and AKT1 identiﬁed in the 43 breast adenomyoepitheliomas analyzed in this study, and in
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NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04128-5 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:1816 | DOI: 10.1038/s41467-018-04128-5 | www.nature.com/naturecommunications 5
AM8
AM46
AM5
HRAS (Q61R)
PIK3CA (E545K)
MDC1 (F326Y)
Pr
im
ar
y 
(A
ME
)
Ip
sil
at
er
a
l b
re
as
t
re
cu
rr
e
n
ce
 (A
ME
)
Ip
sil
at
er
a
l b
re
as
t
re
cu
rr
e
n
ce
 (c
arc
ino
ma
)
Ip
sil
at
er
a
l b
re
as
t
re
cu
rr
e
n
ce
 (tr
a
n
si
tio
n)
Ax
illa
ry
 L
N 
m
et
as
ta
sis
(ep
ith
eli
al)
Ax
illa
ry
 L
N 
m
et
as
ta
sis
(m
yo
e
pi
th
el
ia
l)
HOXB13 (*285E)
PIK3CA (E545K)
HRAS (Q61K)
PIK3R1 (N595Rfs)
PIK3R1 (K567_L570del)
PIK3CA (H1047Y)
TERT (–124 C>T)
USP36 (G924R)
RAPGEF6 (R249*)
TRAK1 (P895T)
STARD4 (T193I)
LIN7C (G133D)
TCF20 (A581V)
MORN4 (R124H)
FAM212a (R152W)
FAM175B (R99H)
MMGT1 (A64Lfs)
TOR4A (R40H)
TREM2 (G17V)
ATAD3A (A264S)
NOTCH1 (G546Rfs)
C10orf120 (N235Kfs)
MUC5B (G2588R)
MAGEA6 (Q90*)
ITGA1 (N1122S)
ADAMTS2 (R207C)
EPHB1 (I812N)
TERT (–124 C>T)
SOX9 (*510S)
SOX2 (E282K)
PALB2 (E272*)
Pr
im
ar
y
(A
ME
)
Pr
im
ar
y
(ca
rci
no
ma
)
Pr
im
ar
y
(A
ME
)
Pr
im
ar
y
(ca
rci
no
ma
)
Ax
illa
ry
 L
N
m
e
ta
st
as
is
Primary (AME)
Primary (AME)
Primary (AME)
Ipsilateral breast recurrence (AME)
Ipsilateral breast recurrence (carcinoma) Axillary LN metastasis (myoepithelial)
Axillary LN metastasis (epithelial)
Ipsilateral breast recurrence (transition)
1.0
1
0
–1
–2
–3
–4
Lo
g2
 ra
tio
Lo
g2
 ra
tio
1
0
–1
–2
–3
–4
Lo
g2
 ra
tio
1
0
–1
–2
–3
–5
–4
Lo
g2
 ra
tio
1
0
–1
–2
–3
Lo
g2
 ra
tio
0.5
0.0
–0.5
–1.0
–1.5
21 3 4 5 6 7 8 9 10 11 12 13 15 16 17 18 19 20 22 21 3 4 5 6 7 8 9 10 11 12 13 15 16 17 18 19 20 22X X
21 3 4 5 6 7 8 9 10 11 12 13 15 16 17 18 19 20 22 21 3 4 5 6 7 8 9 10 11 12 13 15 16 17 18 19 20 22X X
21 3 4 5 6 7 8 9 10 11 12 13 15 16 17 18 19 20 22 21 3 4 5 6 7 8 9 10 11 12 13 15 16 17 18 19 20 22X X
1.0
Lo
g2
 ra
tio
0.5
0.0
–0.5
–1.0
–1.5
–2.0P
IK
3C
A
TE
RT
M
DC
1
CD
KN
2A
HR
AS
HO
XB
3
PI
K3
CA
PI
K3
CA
AT
AD
3A
PI
K3
R1
CD
KN
2A
HR
AS
NO
TC
H1
AD
AM
T5
2
C1
0o
rf*
PI
K3
R1
PI
K3
R1
CD
KN
2A
CD
KN
2A
HR
AS
HR
AS
M
UC
5B
EP
HB
1
TE
RT
TE
RT
PI
K3
CA
TE
RT
M
DC
1
CD
KN
2A
HR
AS
HO
XB
3
PI
K3
CA
TE
RT
M
DC
1
CD
KN
2A
HR
AS
HO
XB
3
PI
K3
CA
TE
RT
M
DC
1
CD
KN
2A
HR
AS
HO
XB
3
PI
K3
CA
TE
RT
M
DC
1
CD
KN
2A
HR
AS
HO
XB
3
PI
K3
CA
TE
RT
M
DC
1
CD
KN
2A
HR
AS
HO
XB
3
PA
LB
2
SO
X9
SO
X2
Chromosome
21 3 4 5 6 7 8 9 10 11 12 13 15 16 17 18 19 20 22 X
Chromosome
21 3 4 5 6 7 8 9 10 11 12 13 15 16 17 18 19 20 22 X
Chromosome
Chromosome
Primary (carcinoma)
Primary (carcinoma)
Axillary LN metastasis
1.0
Lo
g2
 ra
tio
0.5
0.0
–0.5
–1.0
–1.5
–2.0
Lo
g2
 ra
tio
0.5
0.0
–0.5
–1.0
–1.5
1
2
0
–1
–2
–3
Lo
g2
 ra
tio
1
0
–1
–2
–3
Lo
g2
 ra
tio
1
0
–1
–2
–4
–5
–3Lo
g2
 ra
tio
21 3 4 5 6 7 8 9 10 11 12 13 15 16 17 18 19 20 22 X
21 3 4 5 6 7 8 9 10 11 12 13 15 16 17 18 19 20 22 X
21 3 4 5 6 7 8 9 10 11 12 13 15 16 17 18 19 20 22 X
Chromosome
HRAS Q61K
PIK3R1 K567_L570del
PIK3R1 N595Rfs
CDKN2A Hom Del
9p-q loss
NOTCH1 G546Rfs
10p-q loss
AME
Metastasis
Carcinoma
Cancer cell fraction
0%
>0% – 5%
>5% – 20%
>20% – 40%
>40% – 60%
>60% – 80%
>80% – 100%
Clonal mutation
Loss of heterozygosity
3
3
1
21
2
94%
a
b
c
Fig. 4 Progression of breast adenomyoepitheliomas. a−c On the left, heatmaps depicting the cancer cell fractions of the mutations identiﬁed in separately
microdissected, histologically distinct components of AM8, AM46, and AM5; and on the right the copy number genome plots of each component. Cancer
cell fractions were determined using ABSOLUTE12, and color-coded according to the legend. Loss of heterozygosity (LOH) is shown with a diagonal bar.
Clonal mutations are highlighted with orange boxes. Mutations affecting HRAS and/or PI3K-AKT pathway-related genes are highlighted in red. In copy
number genome plots, the genomic position is plotted on the x-axis and the Log2 ratios on the y-axis, and the cancer genes affected by somatic mutations
and any gene affected by subclonal somatic mutations are shown according to their genomic position. a AM8, where the primary adenomyoepithelioma
(AME), separately microdissected components of an ipsilateral relapse in the breast tissue (AME, invasive ductal carcinoma and transition components)
and of separately microdissected components of a metachronous axillary lymph node metastasis (epithelial- and myoepithelial-enriched components)
were analyzed by MSK-IMPACT sequencing. b AM46, where the breast adenomyoepithelioma and spindle cell metaplastic carcinoma components of the
primary tumor were analyzed by MSK-IMPACT sequencing. c AM5, where the breast adenomyoepithelioma and myoepithelial metaplastic carcinoma
components of the primary tumor and a synchronous axillary lymph node metastasis were analyzed by whole-exome sequencing (WES). The phylogenetic
tree was constructed using Treeomics62. The length of the trunk and branches is proportional to the number of mutations deﬁning each trunk or branches.
Likely driver genes and copy number alterations found in the trunk and branches are highlighted in orange. Hom Del, homozygous deletion; LN, lymph node
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mitotic rate (both 46% versus 0%, P= 0.0216, Fisher’s exact
tests), whereas among ER-negative adenomyoepitheliomas, HRAS
mutations were signiﬁcantly associated with necrosis (67% versus
0%, P= 0.0114, Fisher’s exact test) and high mitotic rate (56%
versus 0%, P= 0.0337, Fisher’s exact test).
In the whole dataset (n= 43, Fig. 3), all HRAS (Q61R/K), all
AKT1 (E17K), and 16/24 PIK3CA mutations detected were
known activating hotspot mutations (Fig. 3a). Of the eight non-
hotspot PIK3CA mutations, six affected hotspot residues and all
were predicted to be likely pathogenic (Supplementary Data 3).
While PIK3CA mutations are common in breast cancer
(approximately 35%), mutations in AKT1 and HRAS were found
to be signiﬁcantly less frequent in unselected breast cancers than
in the adenomyoepitheliomas studied here (P < 0.05, Fisher’s
exact tests, Fig. 3b, Supplementary Data 4)6,7. In fact, HRAS
mutations were not found in any of the common-type breast
cancers included in the TCGA study (n = 507)6, and detected
only in one of 560 (0.2%) breast cancers from the whole-genome
sequencing analysis carried out by the International Cancer
Genome Consortium (ICGC)7.
Taken together, adenomyoepitheliomas of the breast are
characterized by low mutation rates and the lack of TP53
mutations. Mutations affecting PI3K-AKT pathway-related genes
are frequent across ER-positive and ER-negative adenomyoe-
pitheliomas. HRAS Q61 hotspot mutations, which are remarkably
rare in breast cancers, are restricted to ER-negative adenomyoe-
pitheliomas and associated with atypical histology indicative of a
more aggressive phenotype.
Adenomyoepitheliomas display limited genomic complexity.
Genome-wide copy number analysis revealed a diploid/near-
diploid genome in the 31 adenomyoepitheliomas analyzed
here (Supplementary Fig. 3a), which harbored fewer copy number
alterations (CNAs) than common forms of breast cancers from
TCGA6 (Supplementary Fig. 3b). Among the most frequent
CNAs were losses of 6p22 (6/31, 19%), 9p21 (CDKN2A, 4/31,
13%), and 4q31 (INPP4B, 2/31, 6%) and gains of 12p12.3 (ETV6,
5/31, 16%) and 5p15 (TERT, 4/31, 13%, Supplementary Fig. 3a).
Losses of 9p21, which have been previously linked to an unfa-
vorable phenotype in breast cancer13, were only detected in
adenomyoepitheliomas lacking ER expression (29% versus 0%, P
= 0.0318, Fisher’s exact test, Supplementary Fig. 3c), and dis-
playing histologic features associated with an unfavorable clinical
behavior (i.e., necrosis and/or high mitotic rate; 36% versus 0%, P
= 0.0105, Fisher’s exact test). An exploratory, hypothesis-
generating genome-wide analysis revealed that ER-negative ade-
nomyoepitheliomas displayed a signiﬁcantly higher number of
CNAs than ER-positive lesions (P= 0.0374, Wilcoxon test, Sup-
plementary Fig. 3d), and adenomyoepitheliomas with atypical
histologic features suggestive of a more aggressive behavior har-
bored signiﬁcantly more CNAs than those without (P= 0.0051,
Wilcoxon test, Supplementary Fig. 3e). Moreover, gains of
chromosomes 7 and 8 were restricted to ER-negative adeno-
myoepitheliomas; however, these were low level gains. Further
studies are warranted to deﬁne their biological and clinical
signiﬁcance.
Homozygous deletions and high-level ampliﬁcations were
rarely found in adenomyoepitheliomas. Of note, recurrent
homozygous deletions affecting CDKN2A were found in 3/14
(21%) ER-negative adenomyoepitheliomas (Fig. 2, Supplementary
Fig. 3f) and, interestingly, these three cases were found to
progress to carcinoma (100% versus 9%, P= 0.011, Fisher’s exact
test). Ampliﬁcations of oncogenes (e.g., FGFR2 and PIK3CA)
were found in individual cases (Fig. 2, Supplementary Fig. 3f), but
none of the adenomyoepitheliomas studied harbored HER2 gene
ampliﬁcation, consistent with the lack of HER2 protein over-
expression by immunohistochemistry (Fig. 1i).
Progression of adenomyoepitheliomas. To assess whether pro-
gression to a malignant phenotype is associated with the acqui-
sition of additional somatic genetic alterations and/or clonal
selection, we analyzed separately microdissected components of
the primary tumor, locally recurrent tumor, and/or lymph node
metastases of three patients with adenomyoepitheliomas (Sup-
plementary Figs. 1m−x).
The separately microdissected components of AM8 and AM46
were subjected to MSK-IMPACT sequencing. In AM8, this
analysis revealed clonal HRAS, PIK3CA, and TERT promoter
mutations and CDKN2A homozygous deletions in all compo-
nents analyzed, consistent with these being truncal (i.e. present as
clonal alterations in all components analyzed) genetic events
(Fig. 4a, Supplementary Data 3). In AM46, two clonal PIK3CA
mutations (Fig. 4b, Supplementary Data 3) were found to be
truncal. The adenomyoepithelioma component likely displayed
intra-tumor genetic heterogeneity, given that it harbored a
subclonal EPHB1 missense mutation and a subclonal TERT
promoter hotspot mutation. Interestingly, the latter was found to
be clonal in the carcinoma component of this case.
These analyses suggested the presence of intra-tumor genetic
heterogeneity within adenomyoepitheliomas and potential clonal
selection in the progression to carcinoma. To investigate these
hypotheses, we performed WES analysis of the separately
microdissected components of AM5. Based on the analysis of
the validated somatic genetic alterations, the adenomyoepithe-
lioma and carcinoma components of the primary tumor and the
axillary lymph node metastasis shared 11 clonal truncal
mutations, including an HRAS and two PIK3R1 mutations, and
a CDKN2A homozygous deletion (Fig. 4c, Supplementary Data 3),
and truncal CNAs including losses of 9p and 9q. Additional
private clonal mutations were found in each of the components,
including a frameshift mutation affecting NOTCH1, which was
coupled with loss of heterozygosity of its wild-type allele due to
the truncal 9q loss, and a loss of chromosome 10 restricted to the
carcinoma. These ﬁndings are consistent with the presence of
intra-tumor genetic heterogeneity within the components ana-
lyzed, and suggest that each component may have undergone
branching evolution (Fig. 4c). Importantly, however, the biologic
signiﬁcance of the private genetic alterations identiﬁed remains to
be deﬁned.
Taken together, our multi-region genetic analyses demonstrate
that adenomyoepitheliomas and their respective carcinomatous
or metastatic components display remarkable similarities in
regards to their mutational and CNA proﬁles, with a limited
number of known driver genetic alterations enriched or solely
detected in the carcinomatous or metastatic components of each
case. In addition, this analysis is consistent with the notion that
HRAS Q61 hotspot mutations, PIK3CA mutations, PIK3R1
mutations, and CDKN2A homozygous deletions, when present,
likely constitute truncal genetic events, whereas TERT promoter
mutations may constitute early or late events in the development
and/or progression of adenomyoepitheliomas.
Impact of HRASQ61R on non-malignant breast epithelial cells.
Given the high prevalence of HRAS Q61 and PIK3CA mutations
in ER-negative adenomyoepitheliomas, and that these mutations
co-occur, we sought to deﬁne the functional impact of these
mutations in non-malignant ER-negative breast epithelial cells.
Given that adenomyoepithelioma cell lines or patient-derived
xenografts are not commercially available, we investigated the
functional impact of forced expression of the HRAS Q61R
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mutation using the non-malignant breast epithelial cells MCF-
10A and MCF-12A. We reasoned that these cell lines would
constitute an adequate model for ER-negative adenomyoepithe-
liomas given their triple-negative phenotype, the fact that they are
TP53 wild-type, and MCF-10A cells harbor a CDKN2A homo-
zygous deletion14, which was the fourth most frequent somatic
genetic alteration identiﬁed in ER-negative adenomyoepithelio-
mas (Fig. 2b). In addition to the parental MCF-10A cells (MCF-
10AP), to deﬁne the impact of concurrent HRASQ61R and
PIK3CA hotspot mutations (i.e., PIK3CAH1047R or PIK3CAE545K),
we employed MCF-10A cells where the oncogenic PIK3CAH1047R
or PIK3CAE545K were knocked-in (MCF-10AH1047R and MCF-
10AE545K, respectively)15.
As expected, forced expression of mutant HRASQ61R in
monolayer MCF-10AP, MCF-10AH1047R, and MCF-12A cells
resulted in upregulation of GTP-bound HRAS (Supplementary
Fig. 4a) and increased ERK1/2 phosphorylation (T202/Y204) as
compared to the empty vector (EV) control (Supplementary
Fig. 4b). We next investigated the oncogenic impact of HRAS
Q61R on non-malignant breast epithelial cells. Forced expression
of mutant HRASQ61R in MCF-10AP, MCF-10AH1047R, and MCF-
12A cells resulted in an increase in colony formation and cell
proliferation as compared to EV or HRASWT in soft agar (Fig. 5a)
and MTT assays (Fig. 5b), respectively. Moreover, forced
expression of mutant HRASQ61R resulted in a signiﬁcantly
increased migration as compared to EV or HRASWT in the three
cell lines, as demonstrated by a wound-healing assay (Fig. 5c,
P < 0.05, unpaired t-tests). Consistent with the observations made
using PIK3CAH1047R cells, forced expression of mutant HRAS in
MCF-10AE545K cells also resulted in increased proliferation and
migration, as compared to EV and HRASWT (Supplementary
Fig. 5a−c). In addition, mammosphere formation assays16
revealed that forced expression of mutant HRASQ61R resulted
in a signiﬁcant increase in the number of spheres than
forced expression of EV or HRASWT in all cell lines tested
(Supplementary Fig. 4c, P < 0.05, unpaired t-tests).
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HRASQ61R induces partial myoepithelial differentiation.
Functional experiments provided evidence that the HRAS Q61R
mutation with or without a PIK3CA H1047R or E545K mutation
results in increased proliferation and migration in non-malignant
breast epithelial cells. Given that HRAS Q61 hotspot mutations
are vanishingly rare in common forms of breast cancers (Fig. 3b),
but present in the majority of ER-negative adenomyoepitheliomas
and always in conjunction with PIK3CA or PIK3R1 somatic
mutations, we posited that HRAS Q61 hotspot mutations would
not only constitute an oncogenic driver of ER-negative adeno-
myoepitheliomas, but also play a role in the acquisition of an
adenomyoepithelial phenotype. To determine the impact of
HRAS and PIK3CA hotspot mutations on the differentiation of
non-malignant breast epithelial cells, we assessed the expression
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levels of proteins preferentially expressed in epithelial or basal/
myoepithelial cells of the breast17,18 in MCF-10AP, MCF-
10AH1047R, MCF-10AE545K, and MCF-12A cells grown in
monolayer, and the phenotypic changes induced by HRAS and
PIK3CA hotspot mutations when MCF-10AP, MCF-10AH1047R,
and MCF-12A cells were grown in three-dimensional model
systems (Fig. 6).
In monolayer cultures, forced expression of mutant HRASQ61R
in MCF-10AH1047R, MCF-10AE545K, and MCF-12A resulted in
downregulation of E-cadherin, which is not expressed in normal
myoepithelial cells19, and upregulation of alpha-smooth muscle
actin (αSMA), an integral component of the smooth muscle
apparatus of myoepithelial cells18 and expressed in adenomyoe-
pitheliomas1, TIMP1, another marker of myoepithelial differ-
entiation18, and vimentin, which is also expressed in
myoepithelial cells of normal breast18 and adenomyoepithelio-
mas2, as compared to EV or forced expression of HRASWT
(Fig. 6a, Supplementary Fig. 5d). In addition, forced expression of
mutant HRASQ61R led to a signiﬁcantly increased ΔN-p63 (p40)/
TA-p63 ratio as compared to EV or forced expression of
HRASWT (Fig. 6a, Supplementary Fig. 5d, P < 0.05, unpaired t-
tests). It should be noted that ΔN-p63 is the p63 isoform
preferentially expressed in cells with myoepithelial
differentiation20,21, whereas TA-p63 is constitutively expressed
at baseline in MCF-10A cells22 and reported to have anti-
suppressive properties23. Consistent with the notion that this
phenomenon is related to the acquisition of a partial myoepithe-
lial phenotype rather than epithelial-to-mesenchymal transition,
the levels of cytokeratin 5 (CK5), which is expressed in epithelial
and myoepithelial cells of normal breast and adenomyoepithe-
liomas1, did not change accordingly (Fig. 6a, Supplementary
Fig. 5d). Quantitative real-time reverse transcription PCR (qRT-
PCR) conﬁrmed the signiﬁcantly higher levels of genes
preferentially expressed in normal myoepithelial cells of the
breast17,18, including ACTA2 (encoding αSMA)1, TIMP1, SPARC,
and VIM (encoding vimentin), and signiﬁcant downregulation of
CDH1 (encoding E-cadherin) in MCF-10AP, MCF-10AH1047R,
and MCF-12A cells expressing mutant HRASQ61R as compared to
cells expressing HRASWT (Supplementary Fig. 4d, P < 0.05,
unpaired t-tests). These observations suggest that forced expres-
sion of mutant HRASQ61R may be sufﬁcient to induce the
acquisition of at least a partial myoepithelial phenotype in non-
malignant breast epithelial cells.
Forced expression of mutant HRASQ61R in MCF-10AP, MCF-
10AH1047R, and MCF-12A cells grown in three-dimensional
organotypic cultures24,25 resulted in a phenotype shift; from
round, regular, polarized acinar structures with hollow lumina to
irregular, multi-acinar structures connected through duct-like
extensions with partially ﬁlled lumina (Fig. 6b), a phenotype
reminiscent of myoepithelial colonies grown in Matrigel26. Akin
to human adenomyoepitheliomas that display markedly
decreased E-cadherin expression in the myoepithelial cells as
compared to the epithelial cells and express vimentin in the
myoepithelial cell layer (Fig. 6c), immunoﬂuorescence analysis of
the acinar structures of MCF-10AP, MCF-10AH1047R, and MCF-
12A cells demonstrated that forced expression of wild-type and
mutant HRAS resulted in downregulation of E-cadherin and
upregulation of vimentin (Fig. 6d). Importantly, however, in
MCF10AH1047R and MCF12A cells, forced expression of mutant
HRASQ61R resulted in vimentin expression in the abluminal
layer, closely recapitulating its expression in the gland-like
structures found in human adenomyoepitheliomas (Fig. 6c). In
addition, forced expression of mutant HRASQ61R led to a
consistent increase in the expression levels of calponin, another
marker of myoepithelial differentiation18,27 expressed in adeno-
myoepitheliomas1, in all cell lines tested (Fig. 6e). qRT-PCR
analysis of RNA extracted from acinar structures corroborated
the downregulation of CDH1 and upregulation of SPARC and
TIMP1 (Supplementary Fig. 4e).
Taken together, these observations are consistent with the
hypothesis that HRASQ61R may be sufﬁcient for the acquisition of
a partial myoepithelial phenotype in ER-negative non-malignant
breast epithelial cells, and that this phenotype becomes more
overt in the presence of a PIK3CA H1047R hotspot mutation.
HRASQ61R induces strong activation of the PI3K-AKT path-
way. Co-occurrence of genetic alterations that induce activation
of MAPK and PI3K-AKT pathways has been shown to result in
stronger oncogenic potential than genetic alterations affecting
either pathway alone28. Given that cross-talks between both
pathways occur and RAS is a positive regulator of AKT28,29, we
sought to investigate whether HRAS Q61 mutations are pre-
ferentially acting via the PI3K-AKT or MAPK signaling cascades,
and the effects of AKT (MK2206) and MEK (GSK212) pharma-
cological inhibition in HRASQ61R-expressing MCF-10AP and
MCF-10AH1047R cells.
We ﬁrst assessed the phosphorylation of the downstream
targets of RAS and AKT at baseline and upon treatment with
AKT and MEK inhibitors (AKTi and MEKi, respectively) at
different time-points (Fig. 7a, Supplementary Fig. 6a). Forced
expression of HRASQ61R as compared to EV resulted in higher
phosphorylation of MAPK signaling pathway components, as
well as of markers downstream of AKT and mTOR, not only in
MCF-10AP, but also in MCF-10AH1047R cells (Fig. 7a, Supple-
mentary Fig. 6a). These ﬁndings suggest that activation of PI3K-
AKT-mTOR pathway is a key consequence of the HRAS Q61R
Fig. 6 Expression of mutant HRASQ61R results in the acquisition of a partial myoepithelial phenotype in non-malignant breast epithelial cells. a
Representative western blot (left) analysis of total protein expression of alpha-smooth muscle actin (αSMA), TIMP1, cytokeratin 5 (CK5), E-cadherin,
vimentin, and nuclear protein expression of ΔN-p63 and TA-p63 in MCF-10AP, MCF-10AH1047R, and MCF-12A cells stably expressing empty vector (EV),
HRASWT, or mutant HRASQ61R. α-Tubulin and Histone H3 were used as protein loading controls for total and nuclear protein expression, respectively.
Quantiﬁcation (right) using LI-COR is shown based on experiments done in triplicate. Comparisons of protein levels were performed between HRASWT and
mutant HRASQ61R, both relative to EV. Error bars, s.d. of mean (n= 3). n.s.= not signiﬁcant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; two-tailed
unpaired t-test. b Representative micrographs of cells cultured in three-dimensional basement membrane for 10 days showing the effects of EV, HRASWT,
or mutant HRASQ61R expression in MCF-10AP, MCF-10AH1047R, and MCF-12A cells on growth and glandular architecture (scale bars, 400 µm). c
Representative micrographs of E-cadherin, vimentin, and calponin immunohistochemical expression in a HRAS and PIK3CA mutant adenomyoepithelioma
(AM32). Note the bi-layered glandular architecture where E-cadherin is preferentially expressed in the inner epithelial layer, whereas vimentin and
calponin decorate the outer myoepithelial layer (scale bars, 50 µm). d, e Representative confocal images of immunoﬂuorescence analysis of d E-cadherin
(green) and vimentin (red) and 4,6-diamidino-2-phenylindole (DAPI, blue; scale bars, 25 µm), and e calponin (green) and DAPI (blue; scale bars, 50 µm) of
MCF-10AP, MCF-10AH1047R, and MCF-12A cells stably expressing EV, HRASWT, or mutant HRASQ61R grown in three-dimensional basement membrane
culture for 10 days. In b, d and e, experiments were independently performed at least three times
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mutation, and that both HRAS Q61 and PIK3CA mutations may
cooperate for strong activation of the PI3K-AKT-mTOR pathway
in ER-negative adenomyoepitheliomas.
Next, we conducted dose−response studies to assess the depen-
dency of RAS-induced proliferation on MAPK or AKT signaling
(Supplementary Fig. 6b). The median inhibitory concentrations
(IC50s) observed suggest that MCF-10AP and MCF-10AH1047R
cells with forced expression of mutant HRASQ61R were less
sensitive to AKT inhibition than those cells expressing EV,
whereas EV- and mutant HRASQ61R-expressing MCF-10AP and
MCF-10AH1047R cells showed similar sensitivity to MEK
inhibition (Supplementary Fig. 6c). In growth factor- and
serum-free media, forced expression of mutant HRASQ61R in
MCF-10AP and MCF-10AH1047R cells revealed a signiﬁcant
increase in cell proliferation (Fig. 7b, P < 0.0001, unpaired t-test),
which was inhibited in part by either AKT or MEK inhibition
regardless of the PIK3CA status. Importantly, however, the
combination of both inhibitors completely abrogated cell
proliferation (Fig. 7c).
To assess the effects of AKT and MEK inhibition further, we
treated EV- or mutant HRASQ61R-expressing MCF-10AP and
MCF-10AH1047R cells grown in three-dimensional cultures. AKT
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and MEK inhibition led to a partial reversion of the phenotypic
transformation caused by mutant HRASQ61R expression in MCF-
10AP and MCF-10AH1047R cells, which was more overt under
treatment with the combination of AKT and MEK inhibitors
(Fig. 7d), consistent with the results obtained in monolayer
cultures.
Taken together, these ﬁndings demonstrate that HRASQ61R
induces strong activation of the PI3K-AKT pathway in non-
malignant breast epithelial cells; however, both PI3K-AKT and
MAPK pathways likely contribute to RAS-mediated proliferation
in these cells.
Discussion
Here we demonstrate that breast adenomyoepitheliomas con-
stitute a heterogeneous group of tumors, characterized by
recurrent pathogenic somatic mutations in HRAS and PI3K-AKT
pathway genes. We further show that the histologic and genetic
features of adenomyoepitheliomas vary according to ER status:
ER-negative adenomyoepitheliomas more frequently display
histologic features associated with an aggressive clinical behavior
and frequently harbor concurrent mutations in HRAS Q61 and
PIK3CA or PIK3R1 (56%), whereas ER-positive adenomyoe-
pitheliomas are largely underpinned by PIK3CA or AKT1
mutations (59%). Members of the PI3K-AKT pathway, including
PIK3CA, PIK3R1, and AKT1, are frequently affected by somatic
genetic alterations in breast cancer6 and breast cancer precursor
lesions30. By contrast, HRAS Q61 hotspot mutations are vanish-
ingly rare in breast cancer6,7, suggesting that in the breast, the co-
occurrence of HRAS Q61 and PI3K pathway gene mutations may
be associated with an adenomyoepithelial phenotype. In fact, the
sole HRAS Q61 mutation found in the TCGA and ICGC breast
cancer datasets was present in a high-grade triple-negative breast
cancer, which was TP53 wild-type and harbored both an HRAS
Q61L and a PIK3CA H1047R mutations7. One could posit that
this invasive breast cancer may have constituted a triple-negative
invasive carcinoma arising from an adenomyoepithelioma.
HRAS and PI3K-AKT pathway mutations identiﬁed by mas-
sively parallel sequencing were found to be clonal in the vast
majority of cases and truncal in the three cases subjected to
sequencing analysis of different components (i.e., primary ade-
nomyoepithelioma, carcinoma and/or metastatic lesions), con-
sistent with the notion that these mutations likely constitute
founder genetic events in the development of adenomyoepithe-
liomas. Given that two cases harbored clonal HRAS mutations
but subclonal PIK3CA or PIK3R1 mutations (Supplementary
Fig. 2), one could posit that the HRAS hotspot mutations may
precede the mutations affecting PI3K pathway genes in the
development of ER-negative adenomyoepitheliomas. The acqui-
sition of additional genetic changes, such as TERT promoter
mutations and CDKN2A homozygous deletions, may play a role
in tumor progression. In fact, an exploratory, hypothesis-
generating analysis of TERT gene promoter mutations and
CDKN2A homozygous deletions in the adenomyoepitheliomas
subjected to massively parallel sequencing revealed a signiﬁcant
association with the presence of a carcinoma (Fig. 2, TERT gene
promoter mutations, P= 0.0307, and CDKN2A homozygous
deletions, P= 0.0086, Fisher’s exact tests). Further larger studies
are warranted to test whether the presence of TERT gene pro-
moter mutations and of loss of p16 protein expression (i.e., the
protein product of CDKN2A) may predict the behavior of ER-
negative adenomyoepitheliomas.
In vitro analyses demonstrated that forced expression of
mutant HRASQ61R alone or in the presence of mutant PIK3-
CAH1047R or PIK3CAE545K results in oncogenic properties and
acquisition of a myoepithelial-like phenotype in non-malignant,
TP53 wild-type, ER-negative breast epithelial cells. Albeit not
necessary for the acquisition of a myoepithelial phenotype, given
that adenomyoepitheliomas lacking HRAS mutations were
observed in this study, forced expression of HRASQ61R was suf-
ﬁcient to induce a partial myoepithelial phenotype. Depending on
the context and culture conditions, myoepithelial differentiation
was more pronounced in cells harboring a knocked-in PIK3-
CAH1047R mutation than in PIK3CAWT cells, suggesting that
these mutations may cooperate in the development and/or
maintenance of the adenomyoepithelioma phenotype. In fact, our
data suggest that mutant HRAS results in strong activation of the
PI3K-AKT-mTOR signaling cascade, enhancing its signaling in a
PIK3CA-mutant background (Fig. 7a, Supplementary Fig. 6a).
Finally, given that the PIK3CA H1047R hotspot mutation, when
introduced in the basal/myoepithelial compartment of mouse
mammary glands, induces the development of tumors that often
recapitulate adenomyoepitheliomas31, further studies are required
to deﬁne whether the likely cell of origin of most ER-negative
breast adenomyoepitheliomas would reside in the basal com-
partment of the mammary gland (where progenitor cells likely
reside32), as opposed to the luminal progenitor compartment, the
origin of the vast majority of breast cancers, including those of
basal-like and triple-negative phenotype33. Consistent with this
notion, MMTV-Wnt1 mice have been shown to develop tumors
that likely originate from progenitor cells34 and display several
characteristics that resemble those of human ER-negative ade-
nomyoepitheliomas, including a basal/myoepithelial tran-
scriptomic proﬁle35, histologic features similar to those of
adenomyoepitheliomas, and Hras Q61 mutations as a somatic
event in up to 37% of cases, exclusively in Trp53 wild-type
lesions36. Conversely, the relevance of the MMTV-H-Ras mouse
model for the study of adenomyoepitheliomas remains to be fully
determined, given that these animals express wild-type rather
than mutant Hras and have histologic features that appear to be
distinct from those of human adenomyoepitheliomas37,
Fig. 7 Impact of AKT and MEK inhibition on PI3K-AKT and MAPK signaling pathways and proliferation in non-malignant breast epithelial cells expressing
mutant HRASQ61R. a Representative western blot analysis of p-ERK1/2 (T202/Y204), p-p90 RSK (S380), p-AKT (S473), p-AKT (T308), p-PRAS40
(T246), p-FOXO1/3a/4, p-GSK3β (S9), p-mTOR (S2448), p-p70 S6K (T389), and p-S6 (S240/244) protein in MCF-10AP and MCF-10AH1047R cells
stably expressing empty vector (EV) or mutant HRASQ61R treated with 2 µM AKT inhibitor (AKTi, MK2206) at different time points. β-actin was used as a
protein loading control. Experiments were repeated at least twice with similar results. b Cell proliferation assay of MCF-10AP and MCF-10AH1047R cells
stably expressing EV or mutant HRASQ61R. ****P < 0.0001; two-tailed unpaired t-test. c Inhibition effects of cells treated with DMSO (black), 1 µM AKTi
(blue), 10 nM MEK inhibitor (MEKi, GSK212, green), and combination of 1 µM AKTi and 10 nM MEKi (red) for 3, 5, and 7 days. In b and c, cells were
cultured in growth factor- and serum-free media. Data are representative of three independent experiments. Error bars, s.d. of mean (n= 3). d
Representative micrographs of MCF-10AP and MCF-10AH1047R cells stably expressing EV or mutant HRASQ61R cultured after 3 days and treated with
DMSO, 1 µM AKTi, 10 nM MEKi, or combination of 1 µM AKT and 10 nM MEK inhibitors for 6 and 9 days are shown (scale bars, 400 µm). DMSO or
inhibitors were added after seeding the cells in three-dimensional basement membrane for 3 days; fresh media with DMSO or inhibitors was replenished
every 3 days. Triplicate experiments were repeated at least twice with similar results
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highlighting that caution should be exercised in the translation of
the genotypic and phenotypic characteristics of mouse mammary
gland tumors to human breast neoplasms.
We and others have demonstrated that rare tumors that ori-
ginate in distinct anatomical sites are not uncommonly under-
pinned by highly recurrent somatic genetic alterations (e.g.,
adenoid cystic carcinomas, which are driven by the MYB-NFIB or
MYBL1 rearrangements in the breast, salivary glands and the
lungs)38,39. Adenomyoepitheliomas, in particular those displaying
an ER-negative phenotype, bear a striking histologic similarity
with epithelial−myoepithelial carcinomas of the salivary glands.
Consistent with the notion that ER-negative adenomyoepithe-
liomas may constitute the breast counterpart of epithelial
−myoepithelial carcinomas of the salivary glands, up to 80% of
salivary gland epithelial−myoepithelial carcinomas have been
reported to harbor HRAS Q61 hotspot mutations40,41, which are
reported to co-occur with PIK3CA mutations in approximately
40% of cases40. Taken together, the genomic analyses presented
here and in previous studies40,41, and the in vitro data generated
here suggest a potential genotypic−phenotypic association, where
HRAS Q61 mutations in conjunction with PIK3CA or PIK3R1
mutations may result in the development of tumors with an
epithelial−myoepithelial phenotype in certain anatomical sites.
Our study has several limitations. Given that cases were
obtained from multiple institutions and consultation ﬁles of the
authors, we could not perform a systematic analysis of the impact
of speciﬁc somatic genetic alterations on the outcome of patients
with adenomyoepithelioma. A subset of adenomyoepitheliomas
lacked mutations in HRAS and/or PI3K-AKT pathway genes, one
of which harbored an ERBB3 hotspot mutation. Further studies
are warranted to deﬁne the genomic drivers of adenomyoe-
pitheliomas lacking HRAS and PI3K-AKT pathway gene muta-
tions. Although we demonstrated here that the HRAS Q61R
hotspot mutation, in particular in association with the PIK3CA
hotspot mutations, may be sufﬁcient for the acquisition of a
myoepithelial phenotype in non-malignant breast epithelial cells
and induces AKT signaling, the mechanistic basis for the acqui-
sition of this myoepithelial differentiation program has yet to be
deﬁned. This would be ideally achieved using patient-derived
adenomyoepithelioma cell lines, xenografts, and organoids, which
are currently not commercially available. Finally, given that the
PIK3CA H1047R hotspot mutation, when introduced in the
basal/myoepithelial compartment of mouse mammary glands,
induces the development of tumors that often recapitulate ade-
nomyoepitheliomas31, further studies are required to deﬁne
whether the likely cell of origin of most ER-negative breast ade-
nomyoepitheliomas would reside in the basal compartment of the
mammary gland.
In conclusion, breast adenomyoepitheliomas are heterogeneous
and genomically distinct on the basis of their ER status. HRAS
Q61 hotspot mutations and mutations affecting PI3K-AKT
pathway-related genes likely constitute drivers of these tumors.
The HRAS Q61R hotspot mutation was found to promote the
acquisition of the cardinal features of ER-negative adenomyoe-
pitheliomas in in vitro models, in particular in the presence of a
PIK3CA H1047R or E545K hotspot mutation. Our ﬁndings
contextualize the biological signiﬁcance of HRAS Q61 hotspot
mutations in the realm of breast neoplasms, and illustrate
genotypic-phenotypic association in the taxonomy of breast
tumors.
Methods
Sample selection and ethics. After obtaining approval by the IRBs and the local
research ethics committees from the authors’ institutions, representative histologic
formalin-ﬁxed parafﬁn-embedded (FFPE) blocks of 53 adenomyoepitheliomas of
the breast were retrieved from the archives of the authors’ institutions. Patient
consent was obtained where appropriate, according to the IRB-approved protocols.
Samples were anonymized prior to the analyses. After central histologic review by
ﬁve pathologists with expertise in breast pathology (F.C.G., M.E., I.O.E., E.A.R.,
and J.S.R.-F.), 43 cases were unanimously diagnosed as breast adenomyoepithe-
lioma following the World Health Organization classiﬁcation (WHO) criteria2, and
were included in this study (Supplementary Data 1). With an estimated mutation
rate of 20 non-synonymous somatic mutations affecting protein coding genes per
case and using Sidak correction (5% overall error rate), a sample size of 43 would
confer 80% power for the detection of a recurrent genetic alteration if its true
incidence is ≥15%. This study is compliant with the Declaration of Helsinki.
Histologic assessment of architectural subtype, necrosis, mitotic rate, nuclear
pleomorphism, and associated carcinomas were performed by three pathologists
(F.C.G., F.P., and J.R.S.-F.). The architectural subtype was deﬁned as tubular or
papillary following previously deﬁned criteria1,2. Necrosis, mitotic rate, and nuclear
pleomorphism have been shown to constitute histologic features associated with
aggressive behavior and malignant transformation in breast
adenomyoepitheliomas1,2. Necrosis was deﬁned as present (any area) or absent.
Mitotic rate was deﬁned as the number of mitotic ﬁgures in the myoepithelial or
epithelial cell compartments per mm2, and stratiﬁed into three categories. Nuclear
pleomorphism was evaluated according to the Nottingham histologic grading
system of breast cancer42. The presence and histologic type of an associated
invasive carcinoma in the primary adenomyoepitheliomas and/or recurrent lesions
in the ipsilateral breast was assessed according to the WHO criteria2.
Immunohistochemistry. Representative 4-μm-thick FFPE tumor sections of each
case were subjected to immunohistochemical analysis with antibodies against ER
(prediluted, clone 6F11, antigen retrieval ER1 solution for 20 min, Leica), and
selected cases were immunohistochemically analyzed for the expression of E-
cadherin (prediluted, clone 36, antigen retrieval CC1 for 16 min, Ventana),
vimentin (prediluted, clone V9, antigen retrieval CC1 for 32 min, Ventana), HER2
(prediluted, 4B5, CC1 for 20 min, Ventana), p63 (prediluted, clone 4A4, antigen
retrieval CC1 for 30 min, Ventana), p53 (prediluted, clone DO-7, antigen retrieval
CC1 for 27 min, Ventana), Ki67 (1:400, clone MIB-1, antigen retrieval CC1 for 30
min, Dako), AR (1:500, clone SP107, antigen retrieval CC1 for 30 min, Ventana)
and calponin (prediluted, clone EP798Y, antigen retrieval CC1 for 16 min, Ven-
tana). Positive and negative controls were included in each slide run. The ER and
HER2 status was deﬁned according to the American Society of Clinical Oncology
(ASCO)/College of American Pathologists (CAP) guidelines43,44. The expression of
E-cadherin, vimentin, calponin, and p63 was analyzed as previously described45.
AR expression was deﬁned as positive when ≥1% of tumor cells displayed nuclear
expression; for statistical comparisons, we used a cut-off of ≥10% that has been
previously employed to select patients for anti-androgen therapy in an early-phase
clinical trial11.
Microdissection and nucleic acid extraction. Eight-µm-thick sections of FFPE
blocks representative of the tumor and normal tissues (i.e. unaffected lymph nodes
or breast tissue devoid of terminal duct-lobular units away from the tumor site)
were stained with nuclear fast red and microdissected using a sterile needle under a
stereomicroscope (Olympus SZ61), to ensure a tumor cell content >80% and that
the normal tissue was devoid of any neoplastic cells as previously described46. DNA
extraction from microdissected tumor samples and normal adjacent tissues was
performed separately using the DNeasy Blood and Tissue Kit (Qiagen), according
to the manufacturer’s guidelines. We obtained DNA of sufﬁcient quantity and
quality of 10, 21, and 12 samples of primary tumors for WES, MSK-IMPACT and
Sanger sequencing only, respectively (Supplementary Data 1). In addition, we
obtained sufﬁcient DNA from separately microdissected components of the pri-
mary tumor, local recurrence in the breast tissue, and/or metastases for three cases
(AM5, AM8, and AM46). DNA quantity and quality were analyzed using a Qubit
Fluorometer (Invitrogen, ThermoFisher) and a TapeStation (Agilent), respectively.
WES and MSK-IMPACT massively parallel sequencing. WES and MSK-
IMPACT, a massively parallel sequencing assay targeting all exons and selected
non-coding and regulatory regions of 410 key cancer genes, were performed at the
Memorial Sloan Kettering Cancer Center (MSKCC) Integrated Genomics Opera-
tion (IGO) on matched tumor and normal DNA samples from 10 and 21 ade-
nomyoepitheliomas, respectively (Supplementary Data 1), as previously
described47,48.
Analyses of the sequencing data and the detection of somatic mutations and
allele-speciﬁc CNAs were performed exactly as previously described47,48. In brief,
reads were aligned to the human reference genome GRCh37 using the Burrows
−Wheeler Aligner49. Local realignment, de-duplication, and quality score
recalibration were performed using the Genome Analysis Toolkit (GATK)50.
Somatic single nucleotide variants (SNVs) were identiﬁed using MuTect51; small
insertions and deletions (indels) were identiﬁed using Strelka and VarScan 252,53,
and further curated by manual inspection. Variants found with >5% global minor
allele frequency in dbSNP (Build 137) or that were covered by <10 reads in the
tumor or <5 reads in the germline were disregarded47,54. Variants for which the
tumor variant allele fraction was <5 times that of the normal variant allele fraction
were disregarded47,54. We adopted this conservative approach to minimize false
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positive results obtained with DNA extracted from FFPE samples47. The potential
functional effect of each missense SNV was investigated following our previously
described approach48,55, using a combination of benchmarked mutation effect
algorithms56. Hotspot mutations were annotated according to Chang et al.57.
Allele-speciﬁc CNAs were inferred from WES or MSK-IMPACT data using
FACETS58 as previously described48,55. In brief, read counts for dbSNP (build 137)
positions within the target regions with dbSNP entries (build 137) were generated
for matched tumor and normal samples, and used as input to FACETS, which
performs a joint segmentation of the total and allelic copy ratio and infers allele-
speciﬁc copy number states, using the following parameters: pre-processing critical
value (Pre CVAL) 50, critical value for estimating diploid Log2 ratio (CVAL1) 150,
critical value for segmentation (CVAL2) 50, and minimum number of
heterozygous SNPs in a segment used for bivariate t-statistic during clustering of
segment (Min Nhet) 25. Genes with CNAs were determined adopting the methods
described in Curtis et al.59 and in the supplementary materials of Piscuoglio et al.47.
The cancer cell fraction (CCF) of each mutation was inferred using ABSOLUTE
(v1.0.6)12, as previously described47,48,55. Solutions from ABSOLUTE were
manually reviewed as described12,60. A mutation was classiﬁed as clonal if its
probability of being clonal was >50%60 or if the lower bound of the 95% conﬁdence
interval of its CCF was >90%61. Mutations that did not meet the above criteria were
considered subclonal. Phylogenetic trees were generated using Treeomics62, using
the CCF values and the depth as input.
Validation of mutations by targeted amplicon re-sequencing. A random subset
of 66 somatic mutations, encompassing 78% of the non-synonymous mutations
identiﬁed by WES in samples AM1−AM7 (excluding case AM5 and its associated
lesions, see below) were validated by targeted amplicon re-sequencing using a
custom Ion Torrent AmpliSeq panel. Sequencing was performed to a median depth
of 832× (range 560×−941×) and 664× (range 257×−949×) for the tumor and
germline samples, respectively. Paired-end reads in FASTQ format were aligned to
the reference human genome GRCh37 using the Torrent Mapping Alignment
Program (TMAP, v3.4.1)63. Local realignment was performed using GATK (v3.1.1)
50. Putative mutations were interrogated using pileup ﬁles generated with samtools
mpileup (version 1.2 htslib 1.2.1)64. Mutations present at variant allele frequencies
>1% were considered “validated”. Mutations that did not validate were excluded
from further analyses. Given the overall validation rate of 92.4% (Supplementary
Data 2), mutations that were not tested were included in the ﬁnal results. For AM5
and its associated lesions, validation was performed through independent WES
assays from new libraries generated from the original DNA samples of each lesion;
only mutations found in both WES assays from each component were considered
as validated.
Sanger sequencing. For validation of the HRAS, PIK3CA, and AKT1 mutations
detected in the samples subjected to WES or MSK-IMPACT sequencing and for
the screening of mutations affecting these genes in additional 12 samples not
subjected to massively parallel sequencing, PCR ampliﬁcation and Sanger
sequencing were performed as previously described47,48 (primer sequences upon
request). In addition, the TERT gene promoter was assessed either by MSK-
IMPACT or Sanger sequencing, using the primers and methods described in
Piscuoglio et al.47. Sequencing reactions were performed in triplicate, and both the
forward and reverse strands were analyzed using MacVector software.
Antibodies and small molecule inhibitors. For western blotting, we employed
antibodies against HRAS (Santa Cruz Biotechnology sc520, rabbit, 1:500), αSMA
(Abcam ab5694, rabbit, 1:500), CK5 (ThermoFisher MA5-17057, mouse, 1:500),
and p63 (Biolegend 619002, rabbit, 1:500), and the following antibodies purchased
from Cell Signaling Technology (CST): rabbit anti-p-MEK (S217/221; 9154,
1:1000), anti-p-ERK1/2 (T202/Y204; 4370, 1:1000), anti-ERK1/2 (9107, 1:1000),
anti-p-p90 RSK (S380; 9341, 1:1000), anti-p-AKT (S473; 4060, 1:1000), anti-p-AKT
(T308; 2965, 1:1000), anti-AKT (9272, 1:1000), anti-p-PRAS40 (T246; 13175,
1:1000), anti-p-FOXO1/3a/4 (2599, 1:1000), anti-p-GSK3β (S9; 5558, 1:1000), anti-
p-mTOR (S2448;5536, 1:1000), anti-p-p70 S6K (T389; 9205, 1:1000), anti-p-S6
(S240/244; 5364, 1:1000), anti-p-4EBP1 (S65; 9451, 1:1000), anti-p-4EBP1 (T37/46;
2855, 1:1000), anti-TIMP1 (8946, 1:1000), anti-vimentin (5741, 1:1000), anti-α-
Tubulin (2125, 1:1000), anti-β-actin (4970, 1:1000) and anti-Histone H3 (4499,
1:1000), and mouse anti-E-cadherin (14472, 1:1000) and anti-α-Tubulin (3873,
1:1000). For immunoﬂuorescence, antibodies against vimentin (CST 5741, rabbit,
1:100), E-cadherin (CST 14472, mouse, 1:50), and calponin (Abcam ab46794
rabbit, 1:100) were used.
The AKT inhibitor MK2206 (MedChem Express HY-10358) and MEK
inhibitor GSK212 (Selleck Chemicals s2658) were employed for pharmacological
inhibition in cell lines analyzed in in vitro experiments time points and
concentrations indicated.
Mutagenesis and vector and stable cell line generation. The human HRAS
(NM_005343) cDNA ORF clone was purchased from Origene (RG216409), and
the Q61R mutation was introduced using the Q5 Site-Directed Mutagenesis Kit
(New England Biolabs E0554) following the manufacturer’s recommendations.
HRASWT and mutant HRASQ61R open reading frames were cloned into the pLenti-
EF1a-GFP-2A-Puro vector (ABM LV067) and pcDNA™3.3-TOPO® vector (Ther-
moFisher K830001) for stable and transient transfection, respectively. Sanger
sequencing was used to conﬁrm the reading frames of HRASWT and HRASQ61R.
Human isogenic MCF-10A PIK3CA wild-type (MCF-10AP) and MCF-12A cells
were purchased from ATCC. PIK3CA H1047R mutant (MCF-10AH1047R) and
E545K mutant (MCF-10AE545K) cells were purchased from Horizon (X-MAN).
Cell lines were authenticated by short tandem repeat proﬁling as previously
described65, and tested for mycoplasma infection using the Universal Mycoplasma
Detection Kit (ATCC). Cell lines were cultured as previously described66. Trans-
fections of EV, HRASWT, and mutant HRASQ61R were performed as previously
described54,66, using Lipofectamine™ LTX Reagent (ThermoFisher 15338100)
according to the manufacturer’s protocol. For stable selection, transfected cells
were selected with 1 µg/ml puromycin. Resistant colonies formed at 15−20 days of
selection.
HRASWT and mutant HRASQ61R activation assay. Pull-down of the active form
of HRAS from stable EV, HRASWT, and mutant HRASQ61R MCF-10AP, MCF-
10AH1047R, and MCF-12A cell lysates was performed using two independent active
HRAS pull-down and detection kits from Cell Biolabs, Inc. (STA-400-H-T) and
ThermoFisher (16117), respectively. Brieﬂy, 80–90% conﬂuent cells from each
group were scraped and collected using the lysis/wash buffer provided. 40 µl to 80
µl of resuspended GST-Raf1-RBD Agarose beads were mixed into each cell lysate
(containing at least 500 µg of total protein) and incubated at 4 °C for 1 h followed
by three washes with 0.5 ml of lysis/wash buffer. Subsequently, the bead pellet was
resuspended in 40−50 µl of 2× reducing SDS-PAGE sample buffer (β-mercap-
toethanol-2× SDS sample buffer 1:20). After centrifugation, the eluted samples
were boiled for 5 min and loaded onto a polyacrylamide gel for GTP-HRAS
detection by western blot analysis using an anti-HRAS antibody.
Western blotting. Total protein and nuclear protein lysates were prepared using
the M-PER Mammalian Protein Extraction Reagent and NE-PER Nuclear and
Cytoplasmic Extraction Reagents, respectively, supplemented with Halt Protease
and Phosphatase inhibitors cocktail (ThermoFisher). Standard western blotting
was conducted as previously described66. Membranes were probed with primary
antibodies and followed by incubation with HRP-tagged (CST 7074) or conjugated
IRDye 680RD/800CW (LI-COR Biosciences) secondary antibodies, visualized on a
Syngene ChemiGenius with Super-Signal West Dura Chemiluminescence Substrate
(Pierce) or the Odyssey Infrared Imaging System, and quantiﬁed by the LI-COR
Image Studio Software. When required, the membranes were stripped using the
Restore PLUS Western Blot Stripping Buffer (ThermoFisher). Replicate experi-
ments were performed as indicated. Unprocessed scans of blots are available in
Supplementary Figs. 7−10.
Colony formation assay. Soft agar colony formation assay was performed as
previously described54,66. Brieﬂy, MCF-10AP, MCF-10AH1047R, and MCF-12A
stably expressing EV, HRASWT, and mutant HRASQ61R (5×104) were added to 1.5
ml of complete growth media with 0.4% UltraPure™ Agarose (ThermoFisher) and
layered onto a 2 ml bed of complete growth media plus 0.5% of agarose. Cells were
fed every 3 days with 1 ml of complete growth media. At day 21, growth media was
removed and viable colonies were stained with 0.005% Crystal Violet solution
(Sigma-Aldrich). Colony size was determined using Fiji (ImageJ). Size (in pixels)
was measured using Feret diameter (D) and minimum Feret diameter (d) and
applying the formula (D x d2)/2= colony volume and plotted with GraphPad
Prism v_7.0a. Experiments were performed in triplicate.
Cell proliferation/viability and dose−response assay. For cell proliferation
assays, cells were seeded either in completed growth media or growth factor- and
serum-free media in 96-well plates, and monitored over 4 or 7 days, as indicated.
Experiments were performed in triplicate. For AKT and MEK pharmacological
inhibition, cells were seeded in complete media or growth factor- and serum-free
media, and inhibitors were added the following day. 25 µl of Resazurin
(R&DSystems, AR002) was added to each well and incubated at 37 °C for 4 h.
Absorbance was read at spectra of 560EX nm/590EM nm using SpectraMax M5
(Molecular Devices). Growth and inhibition curves were plotted and analyzed
using GraphPad Prism v_7.0a. To determine the median inhibitory concentration
(IC50) of the AKT inhibitor and MEK inhibitor, mean values of the number of cells
treated with the indicated inhibitors for 4 days were plotted as percentage of
inhibition against the Log concentration of inhibitors (nM), and nonlinear
regression analysis was performed using GraphPad Prism v_7.0a. Triplicate
experiments were repeated at least twice.
Wound-healing assay. Cells were serum starved for 16 h in 2% horse serum
DMEM/F12 media without EGF, and were trypsinized, seeded (15×105) and cul-
tured overnight in six-well plates. A pipette tip was used to generate a scratch in the
cell layer. Images were obtained at 0 and 24 h after scratch wounding at the same
position. The percentage of wound closure indicated by scratch width reduction
was assessed and plotted using GraphPad Prism v_7.0a. Experiments were per-
formed in triplicate.
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Quantitative real-time reverse transcription PCR. Total RNA was extracted
from cells grown in monolayer or three-dimensional cultures using TRIzol reagent
(ThermoFisher) according to the manufacturer’s instructions. Two micrograms of
the extracted total RNA from each sample were employed for cDNA synthesis
using SuperScript VILO Master Mix (ThermoFisher). cDNA was ampliﬁed using
the StepOnePlus Real-Time PCR System (ThermoFisher). Quantitative TaqMan
RT-PCR (ThermoFisher) was performed for CDH1 (Hs01023894_m1), VIM
(Hs00958111_m1), SPARC (Hs00234160_m1), TIMP1 (Hs00171558_m1), and
ACTA2 (Hs00426835_g1). Experiments were performed in triplicate, and expres-
sion data were normalized to the housekeeping gene GAPDH (Hs99999905_m1)
and calculated as 2–[(Ct of gene)− (Ct of GAPDH)].
Three-dimensional organotypic cultures. Cells were seeded on top of growth
factor-reduced reconstituted basement membrane (Matrigel, BD Biosciences) as
previously described54,66, and subjected to immunoﬂuorescence and mRNA
expression analysis on day 10. Brieﬂy, 50 µl or 200 µl of Matrigel was added to coat
each well of an eight-well chamber slide (for IF staining and pharmacological
inhibition) or a 24-well tissue culture plate (for RNA extraction), respectively. Five
thousand cells resuspended in 500 µl of assay media (with 5 ng/ml EGF and 2%
Matrigel) or 20,000 cells resuspended in 1 ml assay media were plated on top. For
pharmacological inhibition, cells were treated with DMSO or the indicated inhi-
bitors 3 days after seeding in drug-free media. Fresh media with/without DMSO or
the indicated inhibitors was replenished every 3 days. Experiments were repeated at
least twice.
Immunoﬂuorescence. Immunoﬂuorescence analysis of three-dimensional orga-
notypic cultures was performed as previously described67. Acinar structures in
eight-well chambers were ﬁxed and permeabilized in 4% PFA and 0.5% TritonX-
100, respectively. After 1 h blocking in 10% goat serum, primary antibody was
added for overnight incubation at 4 °C, and Alexa Fluor-conjugated secondary
antibody (1:500) was added for 1 h incubation at room temperature. The slides
were mounted in ProLong Gold antifade reagent with DAPI (ThermoFisher).
Confocal analyses were performed with the Leica SP5 DM confocal microscopy
system equipped with four lasers: an ultraviolet (UV) diode (405 nm), an argon
laser (458, 476, 488, and 514 nm), a 543 nm HeNe laser, and a 633 nm HeNe laser.
Experiments were performed in triplicate.
Mammosphere formation assay. Tumor/mammosphere assays were performed
as previously described68. In brief, cells were plated (30,000/well) as single cell
suspensions in ultralow attachment six-well plates and grown in DMEM:F12 media
(serum-free) supplemented with 20 µl/ml B27 (ThermoFisher), 20 ng/ml EGF, and
20 ng/ml bFGF. Fresh media (1 ml) was added every 3 days. Mammospheres were
counted and photographed at day 10. Experiments were performed in triplicate.
Colony and sphere images were documented using the phase contrast EVOS XL
Imaging System (ThermoFisher). Sphere number was determined using Fiji
(ImageJ).
Statistical analysis. Fisher’s exact tests, Wilcoxon tests, and unpaired t-tests were
used for the comparison of categorical, non-parametric, and continuous parametric
variables, respectively. For the comparisons of continuous data, we assessed whe-
ther the variables were heteroscedastic and utilized appropriate statistical methods
accordingly. Mutual exclusivity between PIK3CA, PIK3R1, and AKT1 was assessed
using CoMEt exact test69. Co-occurrence between HRAS mutations and PIK3CA or
PIK3R1 mutations was assessed using a Z test. Statistical analyses were carried out
using R v3.1.2 or GraphPad Prism v_7.0a. Two-tailed P values <0.05 were con-
sidered statistically signiﬁcant. For all experiments, 95% conﬁdence intervals were
adopted.
Data availability. WES and MSK-IMPACT sequencing data have been deposited
in the NCBI Sequence Read Archive under the accession numbers SRP065277 and
SRP065302, respectively. The publicly available dataset from the TCGA6 breast
cancer study was retrieved from the cBioPortal website (www.cBioPortal.org) and
TCGA data portal (https://tcga-data.nci.nih.gov/docs/publications/tcga/) on 07/03/
2017. Somatic mutations from samples included in the ICGC breast cancer study7
were extracted from the supplementary materials of Nik-Zainal et al.7. All other
remaining data are available within the article and Supplementary Files, or avail-
able from the authors upon request.
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